Assessing Atropisomer Axial Chirality in Drug Discovery and Development

ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTAssessing Atropisomer Axial Chirality in Drug Discovery and DevelopmentSteven R. LaPlante*†, Lee D. Fader†, Keith R. Fandrick‡, Daniel R. Fandrick‡, Oliver Hucke†, Ray Kemper‡, Stephen P. F. Miller§, and Paul J. Edwards*†View Author Information† Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Quebec, H7S 2G5, Canada‡ Chemical Development, Non-Clinical Drug Safety, Boehringer Ingelheim Pharmaceutical Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States§ Office of New Drug Quality Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 22, Room…